CARNA BIOSCIENCES

News Release

May 15, 2025
Carna Biosciences, Inc.

Carna Announces Upcoming Poster Presentation of Preliminary Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2025

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that preliminary safety and efficacy results from the ongoing Phase 1b study of docirbrutinib (AS-1763) will be presented at the European Hematology Association (EHA) 2025 Congress which is being held in Milan, Italy June 12-15.

Docirbrutinib, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including a covalent BTK inhibitor (NCT05602363).

The poster will be presented by Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center and all the other principal investigators at the participating clinical sites.

Presentation Details

Abstract Code: PF573

Poster title:	Preliminary Results from a Phase 1b Study of Non-covalent Pan-mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-cell Malignancies
Session:	Poster session
Session date:	June 13, 2025
Presenter:	Nitin Jain[1], Catherine C. Coombs[2], James D'Olimpio[3], Nirav N. Shah[4], Jacqueline Barrientos[5], Seung Tae Lee[6], Andrew Gillis-Smith[7], Shuo Ma[8], Shirou Kirita[9], Masaaki Sawa[9], Kyoko Miyamoto[10], Akinori Arimura[10], William G. Wierda[1], Varsha Gandhi[11], Javier Pinilla-Ibarz[12]

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, 2 Division of Hematology/Oncology, Department of Medicine, University of California Irvine Health, 3 Clinical Research Alliance, 4 Division of Hematology/Oncology, Medical College of Wisconsin, 5 Mount Sinai Medical Center, 6 Greenebaum Comprehensive Cancer, University of Maryland Medical Center, 7 Hematology/Oncology, UMass Chan Medical School/UMass Memorial Medical Center, 8 Division of Hematology-Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, 9 Carna Biosciences, Inc., 10 CarnaBio USA, Inc., 11 Department of Experimental Therapeutics, The University

of Texas MD Anderson Cancer Center, 12 H Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center

The abstract is now available at:

EHA Library - The official digital education library of European Hematology Association (EHA)

About docirbrutinib (AS-1763)

Docirbrutinib is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S - 2 -mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. Docirbrutinib potently inhibited both wild type and those mutant BTKs, strongly suggesting that docirbrutinib will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of docirbrutinib as a next-generation BTK inhibitor. The Phase 1b study of docirbrutinib is being conducted in the U.S. and dosing in the dose expansion part is ongoing (NCT05602363).

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/